Skip to main content

Publications

  1. Sumi Lee, Ahmed R, Ali, Dhulfiqar Ali Abed, Mai-Uyen Nguyen, Michael P. Verzi, Longqin Hu* Structural Modification of C2-substituents on 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N’-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction. Eur. J. Med. Chem. 2024, 265, 116104. Abstract | Full Text: PDF
  2. Jeffrey Yang, Haifa Albanyan, Yiling Wang, Yanhui Yang, Amrik Sahota, Longqin Hu* Development of convenient crystallization inhibition assays for structure-activity relationship studies in the discovery of crystallization inhibitors. Med. Chem. Res. 2023, 32(7), 1391–1399. Full Text: PDF|Full-Text View Only Public Link
  3. Dhulfiqar Abed, Ahmed R. Ali, Sumi Lee, Mai-Uyen Nguyen, Michael P. Verzi, Longqin Hu* Optimization of the C2 substituents on the 1,4-bis(arylsulfonamido)naphthalene-N,N′-diacetic acid scaffold for better inhibition of Keap1-Nrf2 protein-protein interaction. Eur. J. Med. Chem. 2023, 252, 115302. Abstract | Full Text: PDF
  4. Tingying Xie, Husam Zahid, Ahmed R. Ali, Ryan Joyce, Ge Yang, Cassandra Winz, Yicong Le, Renping Zhou, Philip Furmanski1, Longqin Hu, Nanjoo Suh* Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer. Toxicol. Appl. Pharmacol. 2023, 460, 116375. Personal Share Link | Abstract | Full Text: PDF
  5. Alexander L. Ruchelman*, Longqin Hu Special issue of Medicinal Chemistry Research in honor of Professor Edmond J. LaVoie. Med. Chem. Res. 2022, 31(10), 1621-22. Full Text: PDF|Full-Text View Only Public Link 
  6. Jun Wang, Daniel Lam, Jeffrey Yang, Longqin Hu* Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. Med. Chem. Res. 2022, 31(10), 1647-62. Full Text: PDF|Full-Text View Only Public Link
  7. Jeffrey Yang, Subhadwip Basu, Longqin Hu* Design, synthesis, and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway. Med. Chem. Res. 2022, 31(10), 1716-39. Full Text: PDF|Full-Text View Only Public Link
  8. Sumi Lee, Dhulfiqar Abed, Mai-Uyen Nguyen, Michael P. Verzi, Longqin Hu* Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N’-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction. Eur. J. Med. Chem. 2022, 237, 114380. Abstract | Full Text: PDF; Authors Personalized Share Link
  9. Alexander G. Shtukenberg, Longqin Hu, Amrik Sahota, Bart Kahr and Michael D. Ward* Disrupting crystal growth through molecular recognition: designer therapies for kidney stone prevention. Acc. Chem. Res. 2022, 55, 516-525. Abstract | Full Text: PDF
  10. Dhulfiqar Ali Abed, Sumi Lee, Xia Wen, Ahmed R. Ali, Vaibhav Mangipudy, Lauren M. Aleksunes, and Longqin Hu* Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N’-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation. Bioorg. Med. Chem. 2021, 44, 116300. Abstract | Full Text: PDF
  11. Moorthy S. S. Palanki, Michael S. Wolfe, Longqin Hu Editorial: Special issue of Medicinal Chemistry Research in honor of Professor Gary L. Grunewald. Med. Chem. Res. 2021, 30(7), 1317-1320. Full Text: PDF
  12. Ashwini Sadanand Ranade, Joseph R Bertino, Longqin Hu* Design, Synthesis, and Evaluation of Potential Carbamate Prodrugs of 5’-methylthioadenosine (MTA). Med. Chem. Res. 2021, 30(7), 1358-1365. Abstract | Full Text: PDF | Full-Text View Only Public Link |  Preprint
  13. Sumi Lee, Dhulfiqar Ali Abed, Longqin Hu* Development of a homogeneous time-resolved fluorescence energy transfer (TR-FRET) assay for the inhibition of Keap1-Nrf2 protein-protein interaction. SLAS Discov. 2021, 26(1), 100-112. Abstract | Full Text: PDF
  14. Herve Aloysius, Longqin Hu* Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate specific antigen. Med. Chem. Res. 2020, 29(7), 1280-1299. Abstract | Full Text: PDF; Full-Text View Only Public Link
  15. Herve Aloysius, Longqin Hu* Synthesis and evaluation of new 4-peptidamido-2-fluorobenzyl phosphoramide mustard conjugates as prodrugs activated by prostate specific antigen. Med. Chem. Res. 2020, 29(7), 1264-1279. Abstract | Full Text: PDF; Full-Text View Only Public Link
  16. Siming L. Wang, Longqin Hu, Binghe Wang Editorial: In honor of Professor Robert P. Hanzlik on the occasion of his retirement. Med. Chem. Res. 2020, 29(7), 1091-1092. Full Text: PDF
  17. Sumi Lee, Longqin Hu* Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction. Med. Chem. Res. 2020, 29(5), 846-867. Abstract | Full Text: PDF; Full-Text View Only Public Link
  18. Dhulfiqar Ali Abed, Sumi Lee, Longqin Hu* Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction. Bioorg. Med. Chem. 2020, 28(6), 115343. Abstract | Full Text: PDF
  19. Longqin Hu Editorial: Message from the new Editor-in-Chief. Med. Chem. Res. 2020, 29(2), 179. Full Text: PDF
  20. Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Lukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tad A. Holak, Longqin Hu* Design, synthesis, evaluation and structural studies of C2-symmetric small molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) protein-protein interaction. J. Med. Chem. 2019, 62(15), 7250-63. Abstract | Full Text: PDF
  21. Amrik Sahota*, Jay A. Tischfield, David S. Goldfarb, Michael D. Ward, Longqin Hu Cystinuria: Genetic aspects, mouse models, and a new approach to therapy. Urolithiasis 2019, 47(1), 57-66. Abstract | Full Text: PDF
  22. Jeffrey Yang, Longqin Hu* Immunomodulators Targeting the PD-1/PD-L1 Protein-Protein Interaction: From Antibodies to Small Molecules. Med. Res. Rev. 2019, 39(1), 265-301. Abstract | Full Text: PDF
  23. Yanhui Yang, Haifa Albanyan, Sumi Lee, Herve Aloysius, Jian-Jie Liang, Vladyslav Kholodovych, Amrik Sahota, Longqin Hu* Design, synthesis, and evaluation of L-cystine diamides as L-cystine crystallization inhibitors for cystinuria. Bioorg. Med. Chem. Lett. 2018, 28, 1303-1308. SummaryPlus | Full Text + Links | PDF
  24. Jian Shen,* Sadagopan Magesh, Lin Chen, Longqin Hu, Yanan He Enantiomeric characterization and structure elucidation of LH601A using vibrational circular dichroism spectroscopy. Spectrochim. Acta A Mol Biomol Spectrosc. 2018, 192, 312-317. Abstract | Full: HTML / PDF | Supporting Info
  25. Lauren Seabrook,* Longqin Hu* Insects: An underrepresented resource for the discovery of biologically active natural products. Acta Pharm. Sin. B 2017, 7(4), 409–426. Abstract | Full Text + Links | PDF
  26. Laura N. Poloni, Zina Zhu, Nelson G. Vázquez, Anthony Yu, David Connors, Longqin Hu, Amrik Sahota, Michael D. Ward,* Alexander G. Shtukenberg* The role of molecular recognition in L-cystine crystal growth inhibition. Cryst. Growth Des. 2017, 17(5), 2767–2781. Abstract | Full: HTML / PDF | Supporting Info
  27. Longqin Hu,* Yanhui Yang, Herve Aloysius, Haifa Albanyan, Min Yang, Jian-Jie Liang, Anthony Yu, Alexander Shtukenberg, Laura N. Poloni, Vladyslav Kholodovych, Jay A. Tischfield, David Goldfarb, Michael D. Ward, Amrik Sahota L-Cystine Diamides as L-Cystine Crystallization Inhibitors for Cystinuria. J. Med. Chem. 2016, 59(15), 7293-98. Abstract | Full: HTML / PDF | Supporting Info
  28. Jing Zhang, Lu Cheng, Tai-gang Liang, Shurong Ban, Qinshan Li, Longqin Hu Synthesis and Anti-tumor Activities of Novel Amide Compounds. Drugs & Clinic 2016, 31(9), 1313-1318. [CN].
  29. Lu Cheng, Jing Zhang, Tai-gang Liang, Shurong Ban, Qinshan Li, Longqin Hu Synthesis of Novel 3-(4-Fluorophenyl)-4(3H)-pyrimidinone-5-carboxylates. Chem. Reagents 2016, 38(11), 1125-28. [CN].
  30. Fern Toh, Wonmo Suh, Haoxun Wang, Peter Zhou, Longqin Hu, Geofeng You* Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4. Int. J. Biochem. Mol. Biol. 2016, 7(1), 11-18. Abstract | Full Text + Links | PDF
  31. Xinghua Wu and Longqin Hu* Design and Synthesis of Peptide Conjugates of Phosphoramide Mustard as Prodrugs Activated by Prostate-Specific Antigen. Bioorg. Med. Chem. 2016, 24(12), 2697-2706. Abstract | Full Text + Links | PDF
  32. Longqin Hu* Prodrug approaches to drug delivery. In Drug Delivery: Principles and Applications, 2nd Ed., B. Wang, L. Hu, and T. Siahaan, Eds; John Wiley & Sons: Hoboken, New Jersey, 2016; pp 227-271. [Summary | CrossRef]
  33. Binghe Wang, Longqin Hu, and Teruna J.Siahaan, Eds. Drug Delivery: Principles and Applications, 2nd Ed.; John Wiley & Sons: Hobeken, New Jersey, 2016; 697p. [Table of Contents | CrossRef]
  34. Dhulfiqar Ali Abed, Melanie Goldstein, Haifa Albanyan, Huijuan Jin, Longqin Hu* Discovery of Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction as Potential Therapeutic and Preventive Agents (invited review). Acta Pharm. Sin. B 2015, 5(4), 285-299. Abstract | Full Text + Links | PDF
  35. Herve Aloysius and Longqin Hu* Improving the Specificity of the PSA Substrate Glutaryl-Hyp-Ala-Ser-Chg-Gln as a Promoiety. Chem. Biol. Drug Des. 2015, 86(4), 837-848. Abstract | Full Text + Links | PDF
  36. James A. Sullivan, Jie Lun Tong, Martin Wong, Ambika Kumar, Hajrah Sarkar, Sarah Ali, Ikran Hussein, Iqra Zarman, Emma Louise Meredith, Nuala A. Helsby, Longqin Hu and Shane R. Wilkinson* Unravelling the Role of the DNA Repair Enzyme SNM1 in Trypanosoma brucei. Mol. Microbiol. 2015, 96(4), 827–838. Abstract | Full Text: PDF
  37. Xia Wen, Gabriell Thorne, Longqin Hu, Melanie S. Joy, Lauren M. Aleksunes* Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor. J. Biochem. Mol. Toxicol. 2015, 29(6), 261-266. Abstract | Full Text: PDF
  38. Herve Aloysius and Longqin Hu* Targeted prodrug approaches for hormone refractory prostate cancer. Med. Res. Rev. 2015, 35(3) 554-585. Abstract | Full Text: PDF
  39. Lin Chen, Sadagopan Magesh, Hong Wang, Chung S. Yang, Ah-Ng Tony Kong and Longqin Hu* Design and synthesis of novel iminothiazinylbutadienols and divinylpyrimidinethiones as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 2014, 24(3), 940-943. SummaryPlus | Full Text + Links | PDF
  40. Jong hun Lee, Kyeong-Ryoon Lee, Zheng-Yuan Su, Sarandeep Boyanapalli, Dipti Barman, Mou-Tuan Huang, Lin Chen, Magesh Sadagopan, Longqin Hu, Ah-Ng (Tony) Kong* In vitro and in vivo anti-inflammatory effects of a novel 4,6-bis ((E)-4-hydroxy-3-methoxystyryl)-1-phenethylpyrimidine-2(1H)-thione. Chem. Res. Toxicol. 2014, 27(1), 34–41. SummaryPlus | Full Text + Links | PDF
  41. Yanhui Yang, Yu Chen, Herve Aloysius, Daigo Inoyama, and Longqin Hu* Enzymes and Targeted Activation of Prodrugs. in Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agents, H.C. Yang, W.K. Yeh, and J.R. McCarthy, Eds; Wiley & Sons: New York, 2014, pp 165-235. [Summary | CrossRef]
  42. Yongying Jiang and Longqin Hu* Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA). Bioorg. Med. Chem. 2013, 21(23), 7507-7514. SummaryPlus | Full Text + Links | PDF
  43. Grace Buchanan-Kilbey, Joshua Djumpah, Maria V. Papadopoulou, Longqin Hu, Shane R. Wilkinson* and Rachel Ashworth* Evaluating the developmental toxicity of trypanocidal nitroaromatic compounds on zebrafish. Acta Tropica 2013, 128(3), 701–705. SummaryPlus | Full Text + Links | PDF
  44. Andrew A. Voak, Karin Seifert, Edina Balczo, Longqin Hu, Belinda S. Hall and Shane R. Wilkinson* An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs. J. Biol. Chem. 2013, 288, 28466-28476. SummaryPlus | Full Text + Links | PDF
  45. Longqin Hu*, Sadagopan Magesh, Lin Chen, Lili Wang, Timothy A. Lewis, Yu Chen, Carol Khodier, Daigo Inoyama, Lesa J. Beamer, Thomas J. Emge, Jian Shen, John E. Kerrigan, Ah-Ng Tony Kong, Sivaraman Dandapani, Michelle Palmer, Stuart L. Schreiber and Benito Munoz Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg. Med. Chem. Lett. 2013, 23(10), 3039-3043. SummaryPlus | Full Text + Links | PDF
  46. Peng Duan, Shanshan Li, Ni Ai, Longqin Hu, William Welsh, Guofeng You* Potent Inhibitors for Organic Anion Transporters 1 and 3 from Clinical Drug Libraries: Discovery and Molecular Characterization. Mol. Pharmaceut. 2012, 9(11), 3340–3346. SummaryPlus | Full Text + Links | PDF
  47. Yanhui Yang, Andrew Voak, Shane R. Wilkinson, and Longqin Hu* Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation. Bioorg. Med. Chem. Lett. 2012, 22(21), 6583–6586. SummaryPlus | Full Text + Links | PDF
  48. Longqin Hu and Binghe Wang Editorial in honor of the 80th birthday of Professor Lester A. Mitscher. Med. Res. Rev. 2012, 32(4), 685-686. Full Text: PDF
  49. Sadagopan Magesh, Yu Chen, and Longqin Hu* Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 2012, 32(4), 687-726. Abstract | Full Text: PDF
  50. Daigo Inoyama, Yu Chen, Xinyi Huang, Lesa J. Beamer, Ah-Ng Tony Kong, and Longqin Hu* Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction. J. Biomol. Screen. 2012, 17(4), 435-447 . Abstract | Full Text + Links | PDF
  51. Yu Chen, Daigo Inoyama, Ah-Ng Kong, Lesa J. Beamer, and Longqin Hu* Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using Surface Plasmon Resonance. Chem. Biol. Drug Des. 2011, 78(6), 1014-1021. Abstract | Full Text + Links | PDF
  52. Yanhui Yang, Herve Aloysius, Daigo Inoyama, Yu Chen, and Longqin Hu* Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharmaceutica Sinica B 2011, 1(3), 143-159. Abstract | Full Text + Links | PDF
  53. Xinghua Wu, Yu Chen, Herve Aloysius, and Longqin Hu* A novel high-yield synthesis of aminoacyl p-nitroanilines and aminoacyl 7-amino-4-methylcoumarins: important synthons for the synthesis of chromogenic/fluorogenic protease substrates. Beilstein J. Org. Chem. 2011, 7, 1030-1035. HTML | PDF | Album | Supporting Information
  54. Longqin Hu,* Xinghua Wu, Jiye Han, Lin Chen, Simon O. Vass, Patrick Browne, Belinda S. Hall, Christopher Bot, Vithurshaa Gobalakrishnapilla, Peter F. Searle, Richard J. Knox, and Shane R. Wilkinson Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorg. Med. Chem. Lett. 2011, 21(13), 3986-3991. SummaryPlus | Full Text + Links | PDF
  55. Yang Zhao, Mao-Jung Lee, Connie Cheung, Ji-Hyeung Ju, Yu-Kuo Chen, Ba Liu, Longqin Hu, and Chung S. Yang* Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J. Agric. Food Chem. 2010, 58(8), 4844–4852. Abstract | Full Text + Links | PDF
  56. Belinda S. Hall, Xinghua Wu, Longqin Hu, and Shane R. Wilkinson* Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 2010, 54(3), 1193-1199. Abstract | Full Text + Links | PDF
  57. Mansooreh Jaberi-Pour, Simon Vass, Christopher P. Guise, Jane I. Grove, Richard Knox, Longqin Hu, Eva I. Hyde and Peter F. Searle* Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochem. Pharmacol. 2010, 79(2), 102-111. Abstract | Full Text + Links | PDF
  58. Xinghua Wu, Yu Chen, and Longqin Hu* An improved practical synthesis of protected <alpha>-amino selenocarboxylates and its application to the synthesis of N-(<alpha>-aminoacyl)sulfonamides. Tetrahedron Lett. 2009, 50(40), 5585-5588. SummaryPlus | Full Text + Links | PDF
  59. Auemduan Prawan, Constance Lay Lay Saw, Tin Oo Khor, Young-Sam Keum, Siwang Yu, Longqin Hu and Ah-Ng Tony Kong* Anti-NF-KB and anti-inflammatory activities of synthetic isothiocyanates: Effect of chemical structures and cellular signaling. Chem. Biol. Interact. 2009, 179(2-3), 202-211. SummaryPlus | Full Text + Links | PDF
  60. Yongying Jiang, Robert S. DiPaola, and Longqin Hu* Synthesis and stereochemical preference of peptide 4 aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA). Bioorg. Med. Chem. Lett. 2009, 19(9), 2587-2590. SummaryPlus | Full Text + Links | PDF
  61. Yiyu Ge, Xinhua Wu, Dazhi Zhang, and Longqin Hu* 3-Aminoxypropionate-based linker system for cyclization activation in prodrug design. Bioorg. Med. Chem. Lett. 2009, 19(3), 941-944.SummaryPlus | Full Text + Links | PDF
  62. Yu Chen and Longqin Hu* Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 2009, 29(1), 29-64. Abstract | Full Text: PDF
  63. Yongying Jiang and Longqin Hu* N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard. Bioorg. Med. Chem. Lett. 2008, 18(14), 4059-4063.. SummaryPlus | Full Text + Links | PDF
  64. Auemduan Prawan, Young-Sam Keum, Tin Oo Khor, Siwang Yu, Sujit Nair, Wenge Li, Longqin Hu, and Ah-Ng Tony Kong* Structural Influence of Isothiocyanates on the Antioxidant Response Element (ARE)-Mediated Heme Oxygenase-1 (HO-1) Expression. Pharm. Res. 2008, 25(4), 836-844. [Abstract] [Full Text] [PDF]
  65. Young-Sam Keum, Peter Pil-Jae Chang, Ki Han Kwon, Xiaoling Yuan, Wenge Li, Longqin Hu, and Ah-Ng Tony Kong* 3-Morpholinopropyl isothiocyanate (3MP-ITC) is a novel synthetic isothiocyanate that strongly induces the antioxidant response element (ARE)-dependent Nrf2-mediated detoxifying/antioxidant enzymes in vitro and in vivo. Carcinogenesis 2008, 29(3), 594-599. [Abstract] [Full Text] [PDF]
  66. Yongying Jiang, Zhoupeng Zhang, Robert S. DiPaola, and Longqin Hu* Synthesis and epimerization of phenylalanyl 4-aminocyclophosphamides. Tetrahedron 2007, 63(43), 10637-10645. SummaryPlus | Full Text + Links | PDF
  67. Yiyu Ge and Longqin Hu* Microwave-assisted deformylation of N-aryl formamide by KF on basic Al2O3. Tetrahedron Lett. 2007, 48(26), 4585-4588. SummaryPlus | Full Text + Links | PDF
  68. Kumar B. Pabbisetty, Xin Yue, Chen Li, Juha-Pekka Himanen, Renping Zhou, Dimitar B. Nikolov, and Longqin Hu* Kinetic analysis of binding of monomeric and dimeric ephrins to Eph receptors: correlation to function in a growth cone collapse assay. Protein Sci. 2007, 16(3), 355-361. Abstract | Full: HTML/PDF
  69. Xinghua Wu and Longqin Hu* Efficient amidation from carboxylic acids and azides via selenatriazoline: application to the coupling of amino acids and peptides with azides. J. Org. Chem. 2007, 72(3), 765-774. Abstract | Full: HTML / PDF | Supporting Info
  70. Yongying Jiang and Longqin Hu* Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage. Bioorg. Med. Chem. Lett. 2007, 17(2), 517-521. SummaryPlus | Full Text + Links | PDF
  71. Yongying Jiang, Jiye Han, Chengzhi Yu, Simon O. Vass, Peter F. Searle, Patrick Browne, Richard J. Knox, and Longqin Hu* Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzyl phosphoramide mustards for E. coli nitroreductase activation. J. Med. Chem. 2006, 49(14), 4333-4343. Abstract | Full: HTML / PDF | Supporting Info
  72. Prathima Surabhi, Xinghua Wu, and Longqin Hu* Improved solubility and stability of trialkylammonium selenocarboxylate in organic solvents for efficient amidation with azides. Tetrahedron Lett. 2006, 47(27), 4609-4613. SummaryPlus | Full Text + Links | PDF
  73. Raghavendra S. Navath, Kumar B. Pabbisetty, and Longqin Hu* Chemoselective deprotection of N-Boc group in amino acids and peptides by bismuth (III) trichloride. Tetrahedron Lett. 2006, 47(3), 389-393. SummaryPlus | Full Text + Links | PDF
  74. Xinghua Wu and Longqin Hu* Amide bond formation from selenocarboxylates and aromatic azides. Tetrahedron Lett. 2005, 46(28), 8401-8405.SummaryPlus | Full Text + Links | PDF
  75. Longqin Hu* Prodrug approaches to drug delivery. in Drug Delivery: Principles and Applications, B. Wang, T. Siahaan, and R. Soltero, Eds; John Wiley & Sons: Hoboken, New Jersey, 2005; pp 125-165. [Summary | CrossRef]
  76. Peter F Searle,* Ming-Jen Chen, Longqin Hu, Paul R Race, Andrew L Lovering, Jane I Grove, Chris Guise, Mansooreh Jaberipour, Nicholas D James, Vivien Mautner, Lawrence S Young, David J Kerr, Andrew Mountain, Scott A White, and Eva I Hyde Nitroreductase: a prodrug-activating enzyme for gene therapy. Clin. Exp. Pharmacol. Physiol. 2004, 31(11), 811-816. Abstract Full: HTML / PDF
  77. Longqin Hu* Prodrugs: Effective Solutions for Solubility, Permeability, and Targeting Challenges, June 28-29, 2004, Philadelphia, PA, USA, IDrugs 2004, 7(8), 736-742. [IDrugs2004] [PubMed]
  78. Longqin Hu* The prodrug approach to better targeting. Current Drug Discovery 2004, 4(8), 28-32. [CurrentDrugDiscovery2004]
  79. Longqin Hu,* Chengzhi Yu, Yongying Jiang, Jiye Han, Zhuorong Li, Patrick Browne, Paul R. Race, Richard J. Knox, Peter F. Searle, and Eva I. Hyde Nitroaryl Phosphoramides as Novel Prodrugs for E. coli Nitroreductase Activation in Enzyme Prodrug Therapy. J. Med. Chem. 2003, 46(23), 4818 – 4821. Abstract | Full: HTML / PDF | Supporting Info
  80. Zhuorong Li, Jiye Han, Yongying Jiang, Patrick Browne, Richard J. Knox, and Longqin Hu* Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Bioorg. Med. Chem. 2003, 11(19), 4171-4178. SummaryPlus | Full Text + Links | PDF
  81. Bin Liu and Longqin Hu* 5′-(2-Nitrophenylalkanoyl)-2′-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation. Bioorg. Med. Chem. 2003, 11(18), 3889-3899. SummaryPlus | Full Text + Links | PDF
  82. Jun Zhao, Vatee Pattaropong, Yongying Jiang, and Longqin Hu* Facile synthesis and cleavage of imidazolidines in a novel protection strategy for the preparation of peptides containing a reduced amide bioisostere. Tetrahedron Lett. 2003, 44(2), 229-232. SummaryPlus | Full Text + Links | PDF
  83. Yongying Jiang, Jun Zhao, and Longqin Hu* 2,2-Dimethyl-2-(o-nitrophenyl)acetyl (DMNA) as an assisted cleavage protecting group for amines. Tetrahedron Lett. 2002, 43(26), 4589-4592. SummaryPlus | Full Text + Links | PDF
  84. Chengzhi Yu and Longqin Hu* Successful Baylis-Hillman Reaction of Acrylamide with Aromatic Aldehydes. J. Org. Chem. 2002, 67(1), 219-223. Abstract | Full: HTML / PDF | Supporting Info
  85. Chengzhi Yu, Bin Liu, and Longqin Hu* Efficient Baylis-Hillman reaction using stoichiometric base catalyst and an aqueous medium. J. Org. Chem. 2001, 66(16), 5413-5418. Abstract | Full: HTML / PDF | Supporting Info
  86. Chengzhi Yu and Longqin Hu* A facile synthesis of cyclic enecarbamates using Dess-Martin periodinane. Tetrahedron Lett. 2001, 42(31), 5167-5170. SummaryPlus | Full Text + Links | Journal Format-PDF
  87. Chengzhi Yu, Bin Liu and Longqin Hu* Samarium(0) and 1,1′-dioctyl-4,4′-bipyridinium dibromide: a novel electron-transfer system for the chemoselective reduction of aromatic nitro groups. J. Org. Chem. 2001, 66(3), 919-924. Abstract | Full: HTML / PDF | Supporting Info
  88. Chengzhi Yu, Yongying Jiang, Bin Liu and Longqin Hu* A facile synthesis of 2-oxazolidinones via Hofmann rearrangement medicated by bis(trifluoroacetoxy)iodobenzene. Tetrahedron Lett. 2001, 42(8), 1449-1452. SummaryPlus | Full Text + Links | Journal Format-PDF
  89. Chengzhi Yu, Bin Liu and Longqin Hu* A simple one-pot procedure for the conversion of alcohols to azides using phosphate activation. Org. Lett. 2000, 2(13), 1959-1961. Abstract | Full Text – HTML | Full Article – PDF
  90. Chengzhi Yu, Bin Liu and Longqin Hu* A convenient biphasic process for the monosilylation of symmetrical 1,n-primary diols. Tetrahedron Lett. 2000, 41(22), 4281-4285. SummaryPlus | Full Text + Links | Journal Format-PDF
  91. Longqin Hu*, Bin Liu and Douglas R. Hacking 5′-[2-(2-Nitrophenyl)-2-methylpropionyl]-2′-deoxy-5-fluorouridine as a potential bioreductive activated prodrug of FUDR: synthesis, stability, and reductive activation. Bioorg. Med. Chem. Lett. 2000, 10(8), 797-800. SummaryPlus | Full Text + Links | Journal Format-PDF
  92. Chengzhi Yu, Bin Liu and Longqin Hu* A modified procedure for the deprotection of methoxymethyl ether. Tetrahedron Lett. 2000, 41(6), 819-822. SummaryPlus | Full Text + Links | Journal Format-PDF
  93. Longqin Hu and Roberta F. Colman* Resonance Energy transfer between sites in rat liver glutathione S-transferase, 1-1, selectively modified at Cys17 and Cys111. Biochemistry 1997, 36 (7),1635-1645. Abstract | Full: HTML / PDF
  94. Longqin Hu, Barbara L. Borleske and Roberta F. Colman* Probing the active site of alpha-class rat liver glutathione S-transferases using affinity labeling by monobromobimane. Protein Science 1997, 6 (1), 43-52. [Abstract] [Full Text – HTML]
  95. Longqin Hu and Roberta F. Colman* Monobromobimane as an affinity label of the xenobiotic binding site of rat glutathione S-transferase 3-3. J. Biol. Chem. 1995, 270 (37), 21875-21883. [Abstract] [Full Text] [PDF]
  96. Longqin Hu, Preeti Balse and Michael B. Doughty* Neuropeptide Y N-terminal deletion fragments: Correlation between solution structure and receptor binding activity at Y1 receptors in rat brain cortex. J. Med. Chem. 1994, 37 (21), 3622-3629. Abstract | Full Text – PDF
  97. Longqin Hu and Michael B. Doughty* Neuropeptide Y acylation chemistry in aqueous solution: significance to synthesis of a peptide-based photoaffinity label. J. Protein Chem. 1994, 13 (1), 135-140. Abstract | Full Text – PDF
  98. Michael B. Doughty* and Longqin Hu The contribution of helical potential to the in vitro receptor binding activity of a neuropeptide Y N-terminal deletion fragment. Biopolymers 1993, 33 (8), 1195-1206. Abstract | Full Text – PDF
  99. Michael B. Doughty,* Ke Li, Longqin Hu, Shao Song Chu and Richard Tessel Benextramine neuropeptide Y (NPY) binding site interactions: characterization of NPY binding site heterogeneity in rat brain. Neuropeptides 1992, 23 (3), 169-180. [Abstract]
  100. Longqin Hu and Deyu Xu* HPLC separation and characterization of chlorin derivatives with intact ring V from acid degradation products of silkworm excrement crude chlorophyll mixture. Biomed. Chromatogr. (London) 1989, 3(2), 72-74. Abstract | Full Text – PDF
  101. Longqin Hu and Deyu Xu* Studies on photochemodiagnostic and photochemotherapeutic agents for human malignancies III: separation and identification of pheophorbides from the acid degradation products of silkworm excrement crude chlorophyll. Zhongguo Yiyao Gongye Zazhi 1988, 19(4), 157-161 (Ch).
  102. Jun Liu, Longqin Hu, and Deyu Xu* The sensitizing effect of porphyrin derivatives on the photo oxidation of NADPH in deuterium oxide. Academic J. Second Military Med. Univ. (Dier Junyi Daxue Xuebo) 1988, 9(5), 435-437.
  103. Lilin Liu*, Jiqiu Yang, Longqin Hu, Jianguo Lu, Jianhuang Zhao and Yijie Wu Synthesis and antifungal activity of some imidazolyl oxime ether derivatives. J. Med. Coll. PLA 1988, 3(2), 95-99.
  104. Lilin Liu*, Jiqiu Yang, Longqin Hu, Jianguo Lu, Jianhuang Zhao and Yijie Wu Synthesis and antifungal activity of imidazolyl oxime ether derivatives. Academic J. Second Military Med. Univ. (Dier Junyi Daxue Xuebo) 1988, 9(2), 100-105 (Ch).
  105. Longqin Hu and Deyu Xu* On the chemistry of pheophorbide a: A novel photosensitizer. J. Med. Coll. PLA 1987, 2(2), 162-166.
  106. Longqin Hu and Deyu Xu* Pheophorbide a as a novel photosensitizer for the Photodynamic Therapy of Cancer. Academic J. Second Military Med. Univ. (Dier Junyi Daxue Xuebo) 1987, 8(1), 1-6 (Ch).
  107. Longqin Hu and Deyu Xu* On the medical applications of chlorophills and derivatives: a review. World Pharmacy – Synthetics, Biochemicals and Pharmaceutics (Guowei Yiyao – Hechengyao, Shenghuayao, Zhiji) 1987, 8(3), 146-153 (Ch).
  108. Longqin Hu and Deyu Xu* Studies on pheophorbide a as a novel antitumor photosensitizer. Academic J. Second Military Med. Univ. (Dier Junyi Daxue Xuebo) 1986, 7, 405-409 (Ch).

Published Patents

  1. Longqin Hu and Amrik Sahota Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria. US 10,836,737 B2.
  2. Longqin Hu and Haifa Albanyan Cystine Diamide Analogs for Cystinuria. WO2021119475 (US 62/947,799).
  3. Longqin Hu, Dhulfiqar Ali Abed, and Sumi Lee A Homogenous Time-Resolved Fluorescence Energy Transfer (TR-FRET) Assay for the Inhibition of KEAP1-NRF2 Protein-Protein Interaction. U.S. Provisional Application Serial No. 63/031,301.
  4. Longqin Hu and Dhulfiqar Ali Abed Small Molecule Direct inhibitors of Keap1-Nrf2 interaction. PCT/US20/13831.
  5. Longqin Hu, Sadagopan Magesh, Lin Chen, Timothy Lewis, Ben Munos, and Lili Wang Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators. US 10106502 B2.
  6. Longqin Hu and Herve Aloysius New peptide-linked ester prodrugs activated by prostate-specific antigen. PCT Int. Appl. 2018, WO2018144880A1.
  7. Longqin Hu and Amrik Sahota Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria. US9428453 B2.
  8. Longqin Hu and Daigo Inoyama HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction. US 9075070 B2.
  9. Longqin Hu and Amrik Sahota Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria. U.S. Patent Application 2014, US20140187546, pp 31.
  10. Longqin Hu, Sadagopan Magesh, Lin Chen, Timothy Lewis, Ben Munos, and Lili Wang Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators. PCT Int. Appl. 2013, WO 2013067036A1, pp 133.
  11. Longqin Hu, Ah-Ng Tony Kong, Lin Chen, Sadagopan Magesh, and Constance Lay Lay Saw Composition, synthetic process, and use of new antioxidant inflammation modulators. PCT Int. Appl. 2012, WO 2012145420A1, pp 111.
  12. Longqin Hu and Daigo Inoyama HTS fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction. U.S. Pat. Appl. Publ. 2012, US 20120202298A1, pp 20.
  13. Longqin Hu, Shane R. Wilkinson, Xinghua Wu, and Belinda S. Hall Compounds, compositions and methods for treating protozoan infections. PCT Int. Appl. 2011, WO 2011066416A1, pp 40.
  14. Longqin Hu and Xinghua Wu Preparation of peptide-phosphoramide chemotherapeutic conjugates. PCT Int. Appl. 2008, WO 2008067495 A2, pp 57.
  15. Longqin Hu Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation. U.S. Pat. Appl. Publ. 2004, US 20040214798 A1, pp 20.

MyBibliography

Search PubMed for a listing of our publications in Biomedical Journals.

Google Scholar Citations

Search SCOPUS for a listing of our publications from Rutgers.